Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Belgian Body Welcomes Clawback Exemption For Generics/Biosimilars Amid Price Cuts

Executive Summary

Belgian body Medaxes is content with the latest pharmaceutical pricing legislation in the country, which cuts generics and biosimilars prices but also exempts such drugs from pharmaceutical clawback taxes.

You may also be interested in...



Belgian Law Seeks To Tackle Drug Shortages

Belgium is to impose new reporting obligations on pharmaceutical companies that become aware of drug supply interruptions, in a move that is seen by suppliers as less draconian than measures taken in other European countries

Belgian Law Seeks To Tackle Shortages

Legislation that has just been adopted by the Belgian parliament is aiming to tackle shortages by requiring companies to notify local authorities of supply interruptions within three working days, as well as giving pharmacists the option to substitute equivalent alternatives to products in short supply. The new measures limit the risk of excessive sanctions for suppliers, according to local industry association Medaxes.

Accord Gets First EU-Wide Nod For Xarelto Rival

Accord Healthcare has garnered the first positive opinion recommending granting a pan-European marketing authorization for a generic version of rivaroxaban from the EMA’s CHMP. However, originator Bayer claims that no generic competition will be possible for another three years.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel